TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Humana makes dental deal with Sun Life Louisville-based Humana Inc. has formed a relationship with Sun Life Financial Inc. to offer dental-insurance plans to selected employer groups. feeds.bizjournals.com |
Baucus Will Tinker With Health Bill Baucus said he expects to alter his health plan in a bid for support after some Democrats said the bill would impose big costs on middle-income families. online.barrons.com |
Earnings Preview: Lilly Lilly (LLY) is expected to report Q3 earnings Wednesday, October 21 before market open, with a conference call scheduled for 9am ET. GuidanceAnalysts are looking for EPS of $1.02 on revenue of $5.41B. The consensus range is 97c-$1.12 for EPS, and $5.35B-$5.52B for revenue, according to First Call. In July, the company reported Q2 EPS of $1.12, beating analysts' expectations of $1.02 and revenue of $5.29B, which was slightly lower than consensus estimates of $5.28B. On September 14, the company reaffirmed FY09 EPS guidance of $4.20-$4.30. Investors will look forward to Cymbalta sales increasing for Q3. The sales of the anti-cancer drug Erbitux should also help revenues. Negatives for the quarter could come from currency headwinds and the impact of generic competition in the older part of Lilly's pipeline. Complete Story » seekingalpha.com |
BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI Mike Havrilla submits:On 11/16/09, Cytori Therapeutics (NASDAQ: CYTX) completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer. Interim data on the first 32 patients who have reached the six-month follow-up will be presented as a poster at the San Antonio Breast Cancer Symposium on 12/12/0 at 7am (CT) by Mrs. Eva Weiler-Mithoff, MD, lead investigator at the Glasgow Royal Infirmary. Cytori expects to present six-month data for 15-30 patients while final, 12-month data on all patients is expected in early 2011. The ClinicalTrials.gov identifier is NCT00616135 for the RESTORE-2 study, which is a European study designed to evaluate the transplantation of ADRC-enhanced autologous (patient-derived) fat tissue into and around breast deformities. Data from this post-marketing study will also be used to support market adoption and insurance reimbursement for the procedure.Complete Story » seekingalpha.com |
Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market The Burrill Report submits: Eli Lilly (LLY) has acquired global rights to Incyte's (INCY) lead mid-stage therapy for inflammatory and autoimmune diseases for $755 million. The move charts a course for Lilly's expansion into the multi-billion-dollar oral rheumatoid arthritis market, potentially helping quell investor concern about how the company will sustain its revenues once its $5 billion blockbuster Zyprexa loses patent protection in 2011. Revenue from therapies targeting autoimmune diseases, including rheumatoid arthritis, accounted for $16 billion of sales during 2008 according to IMS Health, making them the tenth largest therapeutic class globally. The Lilly agreement makes the perfect tree-topper to Incyte, which got an early gift November 25 when it struck what could turn out to be a $1 billion deal with Novartis (NVS), which licensed ex-U.S. rights for two of its investigational hematology-oncology therapies: INCB18424 for myelofibrosis and INCB28060, a potential treatment for multiple cancers. “This new alliance with Incyte reinforces Lilly's commitment to expand our presence in inflammation and autoimmunity through the development of a new class of oral anti-inflammatory therapies,” says Eiry Roberts, Lilly's vice president for autoimmune product development. For its part, Lilly will pay Incyte $90 million upfront and as much as $665 million in additional milestones and royalty payments on future sales of the drug, INCB28050 if it is successfully commercialized. It is currently being studied in a mid-stage clinical trial for rheumatoid arthritis. Incyte retains an option to co-develop its JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis, an option Incyte said it would consider exercising in the second half of 2010 at the earliest.Complete Story » seekingalpha.com |